Tony De Fougerolles shares his experiences in developing industry-disrupting technologies, meeting LIfT’s CEO Alex Blyth, and his reasons for becoming Chairman of LIfT’s Board of Directors

https://www.dropbox.com/scl/fi/tz89eljmb2so3bakbd3w5/Tony-interview-3.mp4?rlkey=5e311dba2i3br43bn103iovxh&e=1&st=d2it1c50&dl=0

In this interview, Tony de Fougerolles describes his extensive experience in building out drug pipelines in the US and Europe, including at Moderna, Ablynx and most recently as CEO of Evox Therapeutics. Tony explains how he met Alex Blyth, LIfT’s CEO, and expresses his enthusiasm for LIfT’s neutrophil-based therapies, stating that 'LIfT has the potential to unlock a whole new cell type’.